Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | Camrelizumab + Rivoceranib |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Camrelizumab | SHR-1210|INCSHR-1210 | Immune Checkpoint Inhibitor 153 PD-L1/PD-1 antibody 100 | Camrelizumab (SHR-1210) is an antibody that targets PD-1 (PDCD1) and inhibits binding of PD-L1 (CD274) and PD-L2 (PDCD1LG2), potentially resulting in activation of anti-tumor immune response and decreased tumor growth (PMID: 29358502, PMID: 32623573, PMID: 32581041). | |
| Rivoceranib | YN968D1|Apatinib | KIT Inhibitor 55 RET Inhibitor 48 SRC Inhibitor 31 VEGFR2 Inhibitor 36 | Rivoceranib (apatinib) is an inhibitor of receptor tyrosine kinases, including KDR (VEGFR2), RET, c-KIT, Src, and PDGFRa, which may result in reduced cell proliferation and inhibition of tumor growth (PMID: 21443688, PMID: 32669874). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 positive | hepatocellular carcinoma | not predictive | Camrelizumab + Rivoceranib | Clinical Study - Cohort | Actionable | In a Phase II trial (RESCUE), combined Camrelizumab (SHR-1210) and Rivoceranib (apatinib) treatment in patients with CD274 (PD-L1)-positive (TPS>=1%) advanced hepatocellular carcinoma demonstrated a similar objective response rate (31.8%, 7/22 vs. 18.8%, 6/32) and progression-free survival event rate (63.6%,14/22 vs. 75.0%, 24/32) compared to patients with CD274 (PD-L1)-negative (TPS<1%) tumors (PMID: 33087333; NCT03463876). | 33087333 |
| KEAP1 mutant | lung non-squamous non-small cell carcinoma | predicted - sensitive | Camrelizumab + Rivoceranib | Phase Ib/II | Emerging | In a Phase Ib/II trial, non-squamous NSCLC patients harboring KEAP1 and/or STK11 mutations (n=14) demonstrated an improved 12-month survival rate (85.1% vs 53.1%; p=0.01), and a trend towards improved objective response rate (42.9% vs 28.1%; p=0.33), disease control rate (92.9% vs 65.6%, p=0.053), and median progression-free survival (9.4 vs 5.3 months; p=0.64) compared to wild-type KEAP1/STK11 patients (n=32) treated with Camrelizumab (SHR-1210) plus Rivoceranib (apatinib) (PMID: 33323401; NCT03083041). | 33323401 |
| CD274 positive | lung non-squamous non-small cell carcinoma | not predictive | Camrelizumab + Rivoceranib | Phase Ib/II | Actionable | In a Phase Ib/II trial, combined Camrelizumab (SHR-1210) and Rivoceranib (apatinib) treatment in patients with CD274 (PD-L1)-positive (TPS>=1%; n=25) non-squamous non-small cell lung cancer resulted in a similar objective response rate (36.0%, 9/25 vs 22.7%, 15/66; p=0.20), disease control rate (72.0%,18/25 vs 71.2%, 47/66; p=0.94), and median progression-free survival (6.8 vs 5.1 months; p=0.29) to patients with CD274 (PD-L1)-negative (TPS<1%; n=66) tumors (PMID: 33323401; NCT03083041). | 33323401 |
| STK11 mutant | lung non-squamous non-small cell carcinoma | predicted - sensitive | Camrelizumab + Rivoceranib | Phase Ib/II | Emerging | In a Phase Ib/II trial, non-squamous NSCLC patients harboring STK11 and/or KEAP1 mutations (n=14) demonstrated an improved 12-month survival rate (85.1% vs 53.1%; p=0.01), and a trend towards improved objective response rate (42.9% vs 28.1%; p=0.33), disease control rate (92.9% vs 65.6%, p=0.053), and median progression-free survival (9.4 vs 5.3 months; p=0.64) compared to wild-type STK11/KEAP1 patients (n=32) treated with Camrelizumab (SHR-1210) plus Rivoceranib (apatinib) (PMID: 33323401; NCT03083041). | 33323401 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|
CKB BOOST